- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01685814
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV
The investigators propose this study utilizing Lenalidomide, Adriamycin, Dexamethasone (RAD) as comparator arm for Lenalidomide, Bortezomib, Dexamethasone (VRD) with the latter being considered a novel "standard" as an induction protocol, since response in general occurs early after starting treatment we decided to choose three cycles of either induction regimen.
Together with the "novel compounds", tandem high-dose melphalan is still the standard of care; it seems desirable to re-address the question of the number of transplant (single vs. double high-dose melphalan) procedures required in the context of triplet-induction protocols utilizing at least one of the novel compounds.
Thus, the question to be asked in the current protocol is whether immediate lenalidomide maintenance (i.e. following one cycle of high-dose therapy) as an investigational agent will result in identical progression free survival (PFS) when compared to tandem high-dose melphalan with deferred maintenance therapy.
Despite induction with novel compounds, approximately 25 - 40% of patients will be in less than very good partial response. Very recently, achievement of less than VGPR was confirmed to negatively impact on both PFS as well as overall survival (OS). Therefore, allogeneic stem cell transplantation is considered the standard of care in patients with suboptimal response to a first autograft.
In the current protocol, the standard for favourable responders (tandem-autologous transplant) is combined with 3 years of lenalidomide maintenance. This approach will be investigated for patients with less than VGPR following a first autotransplant and compared to the current standard of intensification in poor responders (allogeneic transplantation).
Study Overview
Status
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Aachen, Germany, 52074
- Universitätsklinikum Aachen, Med. Klinik IV, Hämatologie u. Onkologie
-
Berg, Germany, 82335
- Schön Klinik Starnberger See, Hämatologie und Onkologie
-
Berlin, Germany, 13353
- Charité Campus Virchow-Klinikum, Hämatologie, Onkologie u. Tumorimmunologie
-
Bremen, Germany, 28177
- Klinikum Bremen-Mitte gGmbH, Klinik für Innere Medizin I
-
Dresden, Germany, 01307
- Universitätsklinikum Carl Gustav Carus an der TU Dresden, Medizinische Klinik und Poliklinik I
-
Erlangen, Germany, 91054
- Universitätsklinikum Erlangen, Medizinische Klinik 5
-
Flensburg, Germany, 24939
- Malteser Krankenhaus St. Franziskus-Hospital, medizinische Klinik I
-
Frankfurt am Main, Germany, 60596
- Klinikum der Johann Woflgang Goethe Universität, Frankfurt am Mai
-
Frankfurt/Oder, Germany, 15236
- Klinikum Frankfurt (Oder) GmbH Medizinische Klinik I
-
Freiburg, Germany, 79106
- Universitätsklinikum Freiburg, Abteilung für Innere Medizin I
-
Greifswald, Germany, 17475
- Universitätmedizin Greifswald, Klinik und Poliklinik für Innere Medizin C
-
Hamm, Germany, 59071
- St. Marien-Hospital gem. GmbHKna
-
Homburg/Saar, Germany, 66421
- Universitätsklinikum des Saarlandes Innere Medizin I
-
Jena, Germany, 07747
- Klinikum der Friedrich-Schiller-Universität Jena, Klinikum für Innrere Medizin II
-
Karlsruhe, Germany, 76133
- Städtisches Klinikum Karlsruhe Medizinische Klinik III, Abt. Hämatologie u. Onkologie
-
Kiel, Germany, 24105
- Universitätsklinikum Schleswig-Holstein Campus Kiel, II. Med. Poliklinik
-
Kiel, Germany, 24116
- Universitätsklinikum Schleswig-Holstein, Medizinische Klinik und Poliklinik II im städtischen Krankenhaus Kiel
-
Koblenz, Germany, 56068
- Stiftungsklinikum Mittelrhein GmbH, Klinik für Innere Medizin
-
Lübeck, Germany, 23538
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik I
-
Mannheim, Germany, 68167
- Universitätsmedizin Mannheim medizinische Klinik III
-
München, Germany, 80804
- Klinikum Schwabing
-
München, Germany, 81366
- Klinikum der Universität München-Großhadern
-
München, Germany, 81675
- III. Med. Klinik und Poliklinik, Klinikum rechts der Isar der TU München
-
Münster, Germany, 48149
- Universitätsklinikum Münster, Medizinische Klinik u. Poliklinik A
-
Nürnberg, Germany, 90419
- Klinikum Nürnberg Nord, 5. Medizinische LKinik, Onkologie/Hämatologie
-
Oldenburg, Germany, 26133
- Klinikum Oldenburg GmbH, Klinik für Innere Medizin II
-
Regensburg, Germany, 93053
- Uniklinikum Regensburg, Abteilung für Hämatologie und internistische Onkologie
-
Stuttgart, Germany, 70376
- Robert-Bosch-Krankenhaus, Abt. Hämatologie, Onkologie u. Palliativmedizin
-
Ulm, Germany, 89081
- Universitätsklinikum Ulm,Klinik für Innere Medizin III
-
Villingen-Schwenningen, Germany, 78048
- Schwarzwald-Baar Klinkum Villingen-Schwennigen GmbH
-
Wiesbaden, Germany, 65199
- Dr. Horst Schmidt Kliniken, Klinik Innere Medizin III
-
Wuerzburg, Germany, 97080
- Universitätsklinikum Wuerzburg, Medizinische Klinik II
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understand and voluntarily sign an informed consent form
- Patients willing and able to undergo autologous and allogeneic transplantation
- no previous systemic therapy for the treatment of multiple myeloma (dexamethasone at a cumulative dose of 320 mg; plasmapheresis/dialysis without concomitant chemotherapy, local irradiation of bone lesions; and surgical intervention is accepted as pretreatment)
- Newly diagnosed multiple myeloma according to common diagnostic criteria including presence of CRAB and measurable disease parameters
- Cardiac ejection fraction (LVEF) of at least 50%
- Corrected DLCO of at least 50% ; alternatively pO2 [art.] of at least 70mmHg
- Karnofsky performance status of greater or equal to 50%
- adequate bone marrow function
- adequate serum chemistry values
- Use of adequate contraception for female subjects with childbearing potential and male subjects
- Bone marrow sample available for analysis of molecular cytogenetics
- Able to administer low molecular-weight heparin as a prophylactic anticoagulation therapy for the first three months(applicable for subjects randomized to RAD) and able to administer ASS 100 mg/d (applicable for subjects randomized to VRD)
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
- Pregnant or lactating females
- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk
- History of myocardial infarction; NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias; concomitant pericarditis or peri-/myocarditis
- Use of any other experimental drug or therapy within 28 days of baseline
- Greater or equal to Grade 2 peripheral neuropathy on clinical examination within 14 days before enrollment
- Known intolerance of boron
- Hypersensitivity to acyclovir or similar anti-viral drug
- Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer
- HIV positive, active hepatitis B, C or D viral infection, known CMV reactivation/active infection, EBV reactivation/active infection or treponema pallidum infection
- Uncontrolled diabetes mellitus
- Non-secretory MM
- Clinically relevant active infection or serious co-morbid medical conditions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: single stem cell transplant, 3-year lenalidomide maintenance
Arm A
|
Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
|
Experimental: tandem autologous transplant, lenalidomide maintenance
Arm B
|
Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
|
Active Comparator: allogeneic stem cell transplant, lenalidomide maintenance
Arm C
|
Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
|
Experimental: tandem autologous transplant
Arm D
|
Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy endpoint for the induction phase is the rate of patients with CR at first restaging
Time Frame: within 8 days after end of last induction cycle ((Day 92(RAD); Day 71(VRD))
|
within 8 days after end of last induction cycle ((Day 92(RAD); Day 71(VRD))
|
In the consolidation phase the primary efficacy endpoint for comparison II (response <VGPR after first ASCT) is the PFS rate
Time Frame: 3 years after the first ASCT, calculated from day 1 of ASCT.
|
3 years after the first ASCT, calculated from day 1 of ASCT.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ORR following 3 cycles of induction treatment (VRD vs RAD)
Time Frame: within 8 days after end of last induction cycle
|
within 8 days after end of last induction cycle
|
CR and ORR at the end of the whole treatment programme
Time Frame: at the end of the whole treatment programme (approx. 8 years)
|
at the end of the whole treatment programme (approx. 8 years)
|
Overall survival (OS)
Time Frame: 8 years from study entry
|
8 years from study entry
|
Incidence, severity and relationship of SAEs
Time Frame: 30 days post last dosing of study drug
|
30 days post last dosing of study drug
|
Numbers of hospital stays and hospitalization days
Time Frame: within two years from second restaging
|
within two years from second restaging
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Stefan Knop, MD, Wuerzburg University Hospital
- Principal Investigator: Hermann Einsele, MD, Wuerzburg University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Bortezomib
Other Study ID Numbers
- DSMM XIV
- 2009-016616-21 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Previously Untreated Symptomatic Multiple Myeloma
-
Bristol-Myers SquibbAbbottTerminatedNewly Diagnosed, Previously Untreated Multiple MyelomaUnited States, Poland, Italy, Greece
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
Beat AML, LLCRecruitingPreviously Untreated Acute Myeloid LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Alveolar Childhood Rhabdomyosarcoma | Embryonal Childhood Rhabdomyosarcoma | Previously Untreated Childhood RhabdomyosarcomaUnited States
-
Eisai Inc.Quintiles, Inc.TerminatedAdvanced or Metastatic Solid Tumors | Previously Untreated Gastric CancerUnited States, Russian Federation, United Kingdom, Ukraine
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
Merck KGaA, Darmstadt, GermanyCompletedPreviously Untreated Metastatic Colorectal CancerFrance, Italy, Poland, Germany, Hong Kong, Austria, Brazil, Israel, Greece, Argentina, Thailand, Belgium, Australia, Mexico
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple Myeloma | Previously Treated Amyloid Light-chain (AL) AmyloidosisBelgium, United States, United Kingdom, Spain, France, Netherlands
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
Clinical Trials on Lenalidomide, Bortezomib
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
University Hospital, ToulouseDana-Farber Cancer Institute; Celgene Corporation; Janssen-Cilag Ltd.Completed
-
King Faisal Specialist Hospital & Research CenterCompleted
-
Oslo University HospitalHelse Stavanger HF; St. Olavs Hospital; Nordic Myeloma Study GroupActive, not recruiting
-
Massachusetts General HospitalMillennium Pharmaceuticals, Inc.; Celgene CorporationActive, not recruitingAcute Myeloid Leukemia | Myelodysplastic SyndromeUnited States
-
European Myeloma NetworkCompletedMultiple Myeloma | Hematologic MalignanciesSpain, Sweden, Germany, Italy
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Active, not recruitingLymphoma | Neurotoxicity | Therapy-related ToxicityUnited States, Canada
-
Duke UniversityMillennium Pharmaceuticals, Inc.; Duke Cancer InstituteTerminated
-
University of Alabama at BirminghamRecruitingMultiple MyelomaUnited States